Breckenridge Announces FDA Approval for Everolimus Tablets
In an impressive stride towards enhancing healthcare accessibility, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, recently revealed the final FDA approval for Everolimus Tablets for Oral Suspension (TFOS). This generic medication, available in 2mg, 3mg, and 5mg doses, serves as a substitute for AFINITOR DISPERZ®, originally developed by Novartis Pharmaceuticals Corporation. Breckenridge has partnered with Natco Pharma Limited to bring this vital treatment to market, marking an immediate launch shortly after the approval.
The Importance of Everolimus in Treatment Plans
Everolimus TFOS operates as a kinase inhibitor specifically indicated for individuals aged one year and above suffering from tuberous sclerosis complex (TSC). This condition often leads to subependymal giant cell astrocytoma (SEGA), which requires significant therapeutic intervention without the possibility of curative resection. The introduction of this medication enhances the treatment landscape, providing essential options for children and adults facing this health challenge.
Breckenridge's Strategic Vision
This launch exemplifies Breckenridge's dedication to a strategic plan focused on expanding its reach within the institutional healthcare sector while enhancing its product portfolio. By diversifying its range of oncology, autoimmune, and rare disease products, Breckenridge aims to meet the critical health needs of patients in the United States. The mission reflects a fundamental goal of contributing positively to public health and improving access to necessary medicines.
A Commitment to Patient Access
Brian Guy, President and CCO of Breckenridge Pharmaceutical, expresses enthusiasm about this new launch, stating, "Everolimus TFOS's approval highlights our ongoing commitment to increasing access to high-quality and affordable medications for patients in need. Not only does this enhance care in the U.S. healthcare system, but it also aligns with Towa International's broader goal of serving as many patients as possible worldwide." This commitment extends to the introduction of Breckenridge's first copay assistance program, enabling patients to reduce their out-of-pocket expenses significantly.
Implementing the Copay Assistance Program
As part of enhancing patient access to crucial treatments, the launch of Everolimus TFOS will coincide with Breckenridge’s copay assistance initiative, aimed at alleviating financial burdens for patients. This program is designed to help eligible individuals cover out-of-pocket expenses associated with their treatment, thereby improving their ability to manage healthcare costs effectively and adhere to treatment guidelines. This initiative speaks volumes about Breckenridge's aspiration to be a leader in the healthcare domain, particularly within emerging therapeutic areas.
About Breckenridge Pharmaceutical, Inc.
Breckenridge Pharmaceutical, Inc. has established its headquarters in New Jersey and operates as a subsidiary of Towa International, based in Barcelona, Spain. The company collaborates with manufacturers both domestically and internationally to deliver quality, cost-effective generic pharmaceutical products to patients in the U.S. Their focus on customer service, timely deliveries, and quality manufacturing illustrates a commitment to making a significant impact on patient health.
Contact Information for More Inquiries
For additional details regarding Breckenridge's Everolimus TFOS or to explore patient eligibility for their copay assistance program, interested parties may refer to Breckenridge's official website. The commitment to healthcare extends through their external communications and investor relations team, fostering transparency and support for patients.
Frequently Asked Questions
What is the purpose of Everolimus TFOS?
Everolimus TFOS is used to treat subependymal giant cell astrocytoma associated with tuberous sclerosis complex in patients aged one year and older.
How will the copay assistance program help patients?
The copay assistance program aims to reduce the financial burden of treatment for eligible patients, making access to necessary medications more affordable.
Who manufactures Everolimus TFOS?
Everolimus TFOS is manufactured by Natco Pharma Limited under the partnership with Breckenridge Pharmaceutical, Inc.
What are the dosages available for Everolimus TFOS?
Everolimus TFOS is available in 2mg, 3mg, and 5mg dosages, providing flexibility for prescribers in managing patient treatment plans.
How can one learn about the eligibility for Breckenridge's copay assistance?
Patients can find more information regarding their eligibility by visiting the appropriate section on Breckenridge's official website.
